$TAUG Sells Majority Stake of Pilus Energy Subsidiary to Open Therapeutics LLC

Open Therapeutics plans to continue the development of Pilus Energy’s proprietary technology with the ultimate goal of commercialization. Open Therapeutics also agreed Pilus Energy would pay to Tauriga 20% of the net profit generated from Pilus Energy, if any, for each calendar year (or portion thereof) beginning January 1, 2017 (“Profit Sharing Payment”). The Tauriga Profit Sharing Payment will be calculated and paid once per calendar year for the preceding calendar year once Open Therapeutics’ financial statements for such preceding calendar year are finalized by its accountants. However, Tauriga agreed that the first $75,000 owed to the Company under the Profit Sharing Payment shall be retained by Open Therapeutics unless other payment arrangements are reached.

Tauriga’s CEO Seth M. Shaw expressed, “The Company is pleased to have reached this agreement with Open Therapeutics to potentially retain some long term value for its shareholders should Pilus Energy ultimately be successful in commercializing its technology. Open Therapeutics’ CEO, Mr. Jerome Hamilton, has a vision to continue the commercialization process for Pilus Energy. Tauriga’s management intends to be both cooperative and helpful in those mutually beneficial efforts. Lastly and as previously disclosed, the Company believes the actions of Cowan Gunteski significantly damaged Tauriga’s efforts to create shareholder value with respect to Pilus Energy. The Company expects to assert such damages in its ongoing litigation against Cowan Gunteski.”

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company’s previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting its ongoing malpractice lawsuit against its predecessor audit firm, for which it’s seeking monetary damages in excess of $4,000,000 USD.

ABOUT OPEN THERAPEUTICS™ LLC

Open Therapeutics™ is a seven-year-old company that curates and develops open medical, biopharma, and synthetic biology-based biotechnologies. Among the technologies being freely opened to the global community are essential proteins for developing antibiotic and anticancer therapeutics, immunotherapy and oncolytics, and biomarker inducers. The Company is headquartered in Cincinnati, Ohio with laboratory operations in Covington, Kentucky, USA, and Madrid, Spain via its strategic partner, Bacmine SL (www.bacmine.com). For additional information, please visit Open Therapeutics’ website at https://opentherapeutics.org/about-us/.